JP Patent

JP7564869B2 — ホスホジエステラーゼ－４阻害剤の投与からの副作用を低減するための方法

Assigned to アーキュティス・バイオセラピューティクス・インコーポレーテッド · Expires 2024-10-09 · 2y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: JP7564869B2
Jurisdiction: JP
Classification: —
Expires: 2024-10-09
Drug substance claim: No
Drug product claim: No
Assignee: アーキュティス・バイオセラピューティクス・インコーポレーテッド
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.